Review



pegfr (y1173  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc pegfr (y1173
    BUB1 depletion <t>stabilizes</t> <t>EGFR.</t> ( A ) A549 cells were transfected with non-targeting control scrambled (NSS) siRNA or BUB1siRNA. 48 hours post-transfection cells were cross-linked with 100 μM DSS for 30 minutes followed by 30 ng/mL EGF for an additional 30 minutes. Resulting lysates were resolved on SDS-PAGE gels and probed with indicated antibodies. ( B ) Quantitation of western blots from ( A ) only the monomer species of EGFR is plotted. Control siRNA (NSS) transfected, EGF treated lanes were set as 1 fold and used as a baseline for estimating fold enrichment in other samples. ( C ) Quantitation of <t>pEGFR</t> and EGFR dimers from SDS and EGF treated lanes only (lanes 4 and 8 only in A ). NSS transfected lane was set as 1 fold and used as a baseline for estimating fold enrichment in BUB1 siRNA transfected samples. ( D ) Gene expression values from non-metastatic adenocarcinoma samples (N=331) from TCGA lung dataset were log 2 transformed and median centered and correlation coefficient (r) was calculated. BUB1 and EGFR expression is expressed as log 2 transformed values. Correlation coefficient and p-value are listed.
    Pegfr (Y1173, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pegfr+y1173/py1173+egfr+antibody/pmc10373970-45-17-47
    Average 90 stars, based on 1 article reviews
    pegfr (y1173 - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Budding uninhibited by benzimidazoles-1 (BUB1) regulates EGFR signaling by reducing EGFR internalization"

    Article Title: Budding uninhibited by benzimidazoles-1 (BUB1) regulates EGFR signaling by reducing EGFR internalization

    Journal: Aging (Albany NY)

    doi: 10.18632/aging.204820

    BUB1 depletion stabilizes EGFR. ( A ) A549 cells were transfected with non-targeting control scrambled (NSS) siRNA or BUB1siRNA. 48 hours post-transfection cells were cross-linked with 100 μM DSS for 30 minutes followed by 30 ng/mL EGF for an additional 30 minutes. Resulting lysates were resolved on SDS-PAGE gels and probed with indicated antibodies. ( B ) Quantitation of western blots from ( A ) only the monomer species of EGFR is plotted. Control siRNA (NSS) transfected, EGF treated lanes were set as 1 fold and used as a baseline for estimating fold enrichment in other samples. ( C ) Quantitation of pEGFR and EGFR dimers from SDS and EGF treated lanes only (lanes 4 and 8 only in A ). NSS transfected lane was set as 1 fold and used as a baseline for estimating fold enrichment in BUB1 siRNA transfected samples. ( D ) Gene expression values from non-metastatic adenocarcinoma samples (N=331) from TCGA lung dataset were log 2 transformed and median centered and correlation coefficient (r) was calculated. BUB1 and EGFR expression is expressed as log 2 transformed values. Correlation coefficient and p-value are listed.
    Figure Legend Snippet: BUB1 depletion stabilizes EGFR. ( A ) A549 cells were transfected with non-targeting control scrambled (NSS) siRNA or BUB1siRNA. 48 hours post-transfection cells were cross-linked with 100 μM DSS for 30 minutes followed by 30 ng/mL EGF for an additional 30 minutes. Resulting lysates were resolved on SDS-PAGE gels and probed with indicated antibodies. ( B ) Quantitation of western blots from ( A ) only the monomer species of EGFR is plotted. Control siRNA (NSS) transfected, EGF treated lanes were set as 1 fold and used as a baseline for estimating fold enrichment in other samples. ( C ) Quantitation of pEGFR and EGFR dimers from SDS and EGF treated lanes only (lanes 4 and 8 only in A ). NSS transfected lane was set as 1 fold and used as a baseline for estimating fold enrichment in BUB1 siRNA transfected samples. ( D ) Gene expression values from non-metastatic adenocarcinoma samples (N=331) from TCGA lung dataset were log 2 transformed and median centered and correlation coefficient (r) was calculated. BUB1 and EGFR expression is expressed as log 2 transformed values. Correlation coefficient and p-value are listed.

    Techniques Used: Transfection, SDS Page, Quantitation Assay, Western Blot, Expressing, Transformation Assay

    BUB1 inhibition reduces EGFR activation. MDA-MB-231 ( A ) NCI-H358 ( B ) and MRC5 ( C ) cells were serum starved and pre-treated with 10 μM 2OH-BNPP1 for 1 hour followed by 50 ng/mL EGF. Cells were harvested at the indicated time-points (10-180 minutes) after EGF treatment. Whole cell lysates from these samples were resolved on SDS-PAGE gels and transferred to PVDF membranes. The membranes were blocked with 5% de-fatted milk-TBST and probed with pEGFR (Y845), pAKT (S473), and pERK1/2 antibodies. The blots were also probed with antibodies raised against total proteins.
    Figure Legend Snippet: BUB1 inhibition reduces EGFR activation. MDA-MB-231 ( A ) NCI-H358 ( B ) and MRC5 ( C ) cells were serum starved and pre-treated with 10 μM 2OH-BNPP1 for 1 hour followed by 50 ng/mL EGF. Cells were harvested at the indicated time-points (10-180 minutes) after EGF treatment. Whole cell lysates from these samples were resolved on SDS-PAGE gels and transferred to PVDF membranes. The membranes were blocked with 5% de-fatted milk-TBST and probed with pEGFR (Y845), pAKT (S473), and pERK1/2 antibodies. The blots were also probed with antibodies raised against total proteins.

    Techniques Used: Inhibition, Activation Assay, SDS Page

    Inhibition of BUB1 kinase activity reduces EGFR active dimers without affecting inactive-EGFR dimers. A549 ( A ) MRC5 ( B ) and MDA-MB-231-1833 ( C ) cells were serum starved for 3-4 hours, pretreated with 2OH-BNPP1 (10 μM), erlotinib (10 μM) or cetuximab (50 μg/mL) for 1 hour followed by EGF (50 ng/mL) for 10 min. DSS (200 μM) was added for an additional 20 minutes. Total cell lysates were made, resolved on 3-8% gels and probed with pEGFR (Y845), EGFR, Her2 and c-Met antibodies.
    Figure Legend Snippet: Inhibition of BUB1 kinase activity reduces EGFR active dimers without affecting inactive-EGFR dimers. A549 ( A ) MRC5 ( B ) and MDA-MB-231-1833 ( C ) cells were serum starved for 3-4 hours, pretreated with 2OH-BNPP1 (10 μM), erlotinib (10 μM) or cetuximab (50 μg/mL) for 1 hour followed by EGF (50 ng/mL) for 10 min. DSS (200 μM) was added for an additional 20 minutes. Total cell lysates were made, resolved on 3-8% gels and probed with pEGFR (Y845), EGFR, Her2 and c-Met antibodies.

    Techniques Used: Inhibition, Activity Assay

    BUB1 inhibitor reduces endocytosis of active EGFR in MDA-MB-231-1833 cells. ( A ) Cells were plated on glass coverslips, serum starved for 3-4 hours and pretreated with 2OH-BNPP1 (10 μM) or erlotinib (10 μM) for 1 hour followed by EGF treatment (50 ng/mL). Cells were fixed at different time points (5, 20, 40 and 80 minutes) post EGF treatment and processed for staining with pEGFR (Y1068) and EEA1 antibodies. Representative confocal images 20 minutes post EGF treatment are shown. ( B ) co-localization of pEGFR (Y1068) with EEA1 was estimated on ImageJ using JACOMP plugin. Data at 20 min post EGF treatment is plotted. Two-sided students t-test was performed on MS-Excel (p values, ** = 0.00097, ***=3.17 X 10 -5 ).
    Figure Legend Snippet: BUB1 inhibitor reduces endocytosis of active EGFR in MDA-MB-231-1833 cells. ( A ) Cells were plated on glass coverslips, serum starved for 3-4 hours and pretreated with 2OH-BNPP1 (10 μM) or erlotinib (10 μM) for 1 hour followed by EGF treatment (50 ng/mL). Cells were fixed at different time points (5, 20, 40 and 80 minutes) post EGF treatment and processed for staining with pEGFR (Y1068) and EEA1 antibodies. Representative confocal images 20 minutes post EGF treatment are shown. ( B ) co-localization of pEGFR (Y1068) with EEA1 was estimated on ImageJ using JACOMP plugin. Data at 20 min post EGF treatment is plotted. Two-sided students t-test was performed on MS-Excel (p values, ** = 0.00097, ***=3.17 X 10 -5 ).

    Techniques Used: Staining

    Related Articles

    other:

    Article Title: Resistance to RET-inhibition in RET-rearranged NSCLC is mediated by reactivation of RAS/MAPK signaling
    Article Snippet: Antibodies used were as follows: pEGFR Y1068 (D7A5), pEGFR Y1173 (53A5), total RET (D3D8R), pERK1/2 XP T202/Y204 (D13.14.4E), total ERK1/2 (L34F12), pAKT S473 XP (D9E), total AKT (40D4), and pSHC1 Y239/Y240 (2434) from Cell Signaling; pTYR (4G10 Platinum), GAPDH (6C5) and GAPDH (ABS16) from Millipore; pRET Y1062, α-tubulin (TU-02) and NRAS (F155) from Santa Cruz Biotechnology.

    Article Title: Mevastatin promotes healing by targeting caveolin-1 to restore EGFR signaling
    Article Snippet: Cells were analyzed using a Zeiss LSM780 confocal microscope and images were acquired with Zen software.

    Immunofluorescence:

    Article Title: Mevastatin promotes healing by targeting caveolin-1 to restore EGFR signaling
    Article Snippet: HEKs were grown to approximately 30% confluency and switched to basal media for 24 hours and treated with 5 μM mevastatin, 150 nM tyrphostin AG 1478 (Cell Signaling Technology), or both in combination, and 12.5 ng/ml EGF treatment for 5 minutes served as a positive control. .. For immunofluorescence staining, tissue sections of discarded DFUs were treated with mevastatin as described above and used for staining with anti–phospho-EGFR (Y1173) (53A5) (rabbit, 1:100; Cell Signaling Technology; 4407) or anti-Cav1 (D46G3) (rabbit, 1:200; Cell Signaling Technology; 3267). pEGFR (Y1173) and Cav1 staining was visualized with Alexa Fluor 488–conjugated goat anti–rabbit antibody (1:500; Invitrogen; A11008) and mounted with Prolong DAPI Gold antifade reagent (Invitrogen) to visualize cell nuclei. .. Tissue sections of porcine wounds were stained with anti–Cav1 antibody (rabbit, 1:200; Cell Signaling Technology; 3267) diluted in 1% normal goat serum with 0.3% Triton X-100, followed by Rabbit-on-Farma HRP-Polymer (Biocare Medical) and then developed using Betazoid DAB Chromogen Kit (Biocare Medical).

    Staining:

    Article Title: Mevastatin promotes healing by targeting caveolin-1 to restore EGFR signaling
    Article Snippet: HEKs were grown to approximately 30% confluency and switched to basal media for 24 hours and treated with 5 μM mevastatin, 150 nM tyrphostin AG 1478 (Cell Signaling Technology), or both in combination, and 12.5 ng/ml EGF treatment for 5 minutes served as a positive control. .. For immunofluorescence staining, tissue sections of discarded DFUs were treated with mevastatin as described above and used for staining with anti–phospho-EGFR (Y1173) (53A5) (rabbit, 1:100; Cell Signaling Technology; 4407) or anti-Cav1 (D46G3) (rabbit, 1:200; Cell Signaling Technology; 3267). pEGFR (Y1173) and Cav1 staining was visualized with Alexa Fluor 488–conjugated goat anti–rabbit antibody (1:500; Invitrogen; A11008) and mounted with Prolong DAPI Gold antifade reagent (Invitrogen) to visualize cell nuclei. .. Tissue sections of porcine wounds were stained with anti–Cav1 antibody (rabbit, 1:200; Cell Signaling Technology; 3267) diluted in 1% normal goat serum with 0.3% Triton X-100, followed by Rabbit-on-Farma HRP-Polymer (Biocare Medical) and then developed using Betazoid DAB Chromogen Kit (Biocare Medical).



    Similar Products

    pegfr y1173 antibodies (44-794g)  (Thermo Fisher)
    90
    Thermo Fisher pegfr y1173 antibodies (44-794g)
    Pegfr Y1173 Antibodies (44 794g), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pegfr+y1173/pm36470425-373-32-37
    Average 90 stars, based on 1 article reviews
    pegfr y1173 antibodies (44-794g) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    pegfr (y1173  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc pegfr (y1173
    BUB1 depletion <t>stabilizes</t> <t>EGFR.</t> ( A ) A549 cells were transfected with non-targeting control scrambled (NSS) siRNA or BUB1siRNA. 48 hours post-transfection cells were cross-linked with 100 μM DSS for 30 minutes followed by 30 ng/mL EGF for an additional 30 minutes. Resulting lysates were resolved on SDS-PAGE gels and probed with indicated antibodies. ( B ) Quantitation of western blots from ( A ) only the monomer species of EGFR is plotted. Control siRNA (NSS) transfected, EGF treated lanes were set as 1 fold and used as a baseline for estimating fold enrichment in other samples. ( C ) Quantitation of <t>pEGFR</t> and EGFR dimers from SDS and EGF treated lanes only (lanes 4 and 8 only in A ). NSS transfected lane was set as 1 fold and used as a baseline for estimating fold enrichment in BUB1 siRNA transfected samples. ( D ) Gene expression values from non-metastatic adenocarcinoma samples (N=331) from TCGA lung dataset were log 2 transformed and median centered and correlation coefficient (r) was calculated. BUB1 and EGFR expression is expressed as log 2 transformed values. Correlation coefficient and p-value are listed.
    Pegfr (Y1173, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pegfr+y1173/py1173+egfr+antibody/pmc10373970-45-17-47
    Average 90 stars, based on 1 article reviews
    pegfr (y1173 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    pegfr(y1173) antibody  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc pegfr(y1173) antibody
    BUB1 depletion <t>stabilizes</t> <t>EGFR.</t> ( A ) A549 cells were transfected with non-targeting control scrambled (NSS) siRNA or BUB1siRNA. 48 hours post-transfection cells were cross-linked with 100 μM DSS for 30 minutes followed by 30 ng/mL EGF for an additional 30 minutes. Resulting lysates were resolved on SDS-PAGE gels and probed with indicated antibodies. ( B ) Quantitation of western blots from ( A ) only the monomer species of EGFR is plotted. Control siRNA (NSS) transfected, EGF treated lanes were set as 1 fold and used as a baseline for estimating fold enrichment in other samples. ( C ) Quantitation of <t>pEGFR</t> and EGFR dimers from SDS and EGF treated lanes only (lanes 4 and 8 only in A ). NSS transfected lane was set as 1 fold and used as a baseline for estimating fold enrichment in BUB1 siRNA transfected samples. ( D ) Gene expression values from non-metastatic adenocarcinoma samples (N=331) from TCGA lung dataset were log 2 transformed and median centered and correlation coefficient (r) was calculated. BUB1 and EGFR expression is expressed as log 2 transformed values. Correlation coefficient and p-value are listed.
    Pegfr(y1173) Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pegfr+y1173/p+egfr+antibody/pmc10272518-40-5-20
    Average 90 stars, based on 1 article reviews
    pegfr(y1173) antibody - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    pegfr  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc pegfr
    BUB1 depletion <t>stabilizes</t> <t>EGFR.</t> ( A ) A549 cells were transfected with non-targeting control scrambled (NSS) siRNA or BUB1siRNA. 48 hours post-transfection cells were cross-linked with 100 μM DSS for 30 minutes followed by 30 ng/mL EGF for an additional 30 minutes. Resulting lysates were resolved on SDS-PAGE gels and probed with indicated antibodies. ( B ) Quantitation of western blots from ( A ) only the monomer species of EGFR is plotted. Control siRNA (NSS) transfected, EGF treated lanes were set as 1 fold and used as a baseline for estimating fold enrichment in other samples. ( C ) Quantitation of <t>pEGFR</t> and EGFR dimers from SDS and EGF treated lanes only (lanes 4 and 8 only in A ). NSS transfected lane was set as 1 fold and used as a baseline for estimating fold enrichment in BUB1 siRNA transfected samples. ( D ) Gene expression values from non-metastatic adenocarcinoma samples (N=331) from TCGA lung dataset were log 2 transformed and median centered and correlation coefficient (r) was calculated. BUB1 and EGFR expression is expressed as log 2 transformed values. Correlation coefficient and p-value are listed.
    Pegfr, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pegfr+y1173/Phospho-EGF+Receptor+(Tyr1173)+Rabbit+mAb/pm36989239-42-6-33
    Average 96 stars, based on 1 article reviews
    pegfr - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    anti pegfr y1173  (Danaher Inc)
    86
    Danaher Inc anti pegfr y1173
    BUB1 depletion <t>stabilizes</t> <t>EGFR.</t> ( A ) A549 cells were transfected with non-targeting control scrambled (NSS) siRNA or BUB1siRNA. 48 hours post-transfection cells were cross-linked with 100 μM DSS for 30 minutes followed by 30 ng/mL EGF for an additional 30 minutes. Resulting lysates were resolved on SDS-PAGE gels and probed with indicated antibodies. ( B ) Quantitation of western blots from ( A ) only the monomer species of EGFR is plotted. Control siRNA (NSS) transfected, EGF treated lanes were set as 1 fold and used as a baseline for estimating fold enrichment in other samples. ( C ) Quantitation of <t>pEGFR</t> and EGFR dimers from SDS and EGF treated lanes only (lanes 4 and 8 only in A ). NSS transfected lane was set as 1 fold and used as a baseline for estimating fold enrichment in BUB1 siRNA transfected samples. ( D ) Gene expression values from non-metastatic adenocarcinoma samples (N=331) from TCGA lung dataset were log 2 transformed and median centered and correlation coefficient (r) was calculated. BUB1 and EGFR expression is expressed as log 2 transformed values. Correlation coefficient and p-value are listed.
    Anti Pegfr Y1173, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pegfr+y1173/pm36374715-118-65-71
    Average 86 stars, based on 1 article reviews
    anti pegfr y1173 - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    pegfr  (R&D Systems)
    93
    R&D Systems pegfr
    BUB1 depletion <t>stabilizes</t> <t>EGFR.</t> ( A ) A549 cells were transfected with non-targeting control scrambled (NSS) siRNA or BUB1siRNA. 48 hours post-transfection cells were cross-linked with 100 μM DSS for 30 minutes followed by 30 ng/mL EGF for an additional 30 minutes. Resulting lysates were resolved on SDS-PAGE gels and probed with indicated antibodies. ( B ) Quantitation of western blots from ( A ) only the monomer species of EGFR is plotted. Control siRNA (NSS) transfected, EGF treated lanes were set as 1 fold and used as a baseline for estimating fold enrichment in other samples. ( C ) Quantitation of <t>pEGFR</t> and EGFR dimers from SDS and EGF treated lanes only (lanes 4 and 8 only in A ). NSS transfected lane was set as 1 fold and used as a baseline for estimating fold enrichment in BUB1 siRNA transfected samples. ( D ) Gene expression values from non-metastatic adenocarcinoma samples (N=331) from TCGA lung dataset were log 2 transformed and median centered and correlation coefficient (r) was calculated. BUB1 and EGFR expression is expressed as log 2 transformed values. Correlation coefficient and p-value are listed.
    Pegfr, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pegfr+y1173/Human+Phospho-EGFR+(Y1173)+Antibody/us11459391-492-24-28
    Average 93 stars, based on 1 article reviews
    pegfr - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    pegfr y1173  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc pegfr y1173
    BUB1 depletion <t>stabilizes</t> <t>EGFR.</t> ( A ) A549 cells were transfected with non-targeting control scrambled (NSS) siRNA or BUB1siRNA. 48 hours post-transfection cells were cross-linked with 100 μM DSS for 30 minutes followed by 30 ng/mL EGF for an additional 30 minutes. Resulting lysates were resolved on SDS-PAGE gels and probed with indicated antibodies. ( B ) Quantitation of western blots from ( A ) only the monomer species of EGFR is plotted. Control siRNA (NSS) transfected, EGF treated lanes were set as 1 fold and used as a baseline for estimating fold enrichment in other samples. ( C ) Quantitation of <t>pEGFR</t> and EGFR dimers from SDS and EGF treated lanes only (lanes 4 and 8 only in A ). NSS transfected lane was set as 1 fold and used as a baseline for estimating fold enrichment in BUB1 siRNA transfected samples. ( D ) Gene expression values from non-metastatic adenocarcinoma samples (N=331) from TCGA lung dataset were log 2 transformed and median centered and correlation coefficient (r) was calculated. BUB1 and EGFR expression is expressed as log 2 transformed values. Correlation coefficient and p-value are listed.
    Pegfr Y1173, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pegfr+y1173/Bif-1+Antibody/bio_rxiv__2022__09__23__509246-186-14-5
    Average 93 stars, based on 1 article reviews
    pegfr y1173 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    BUB1 depletion stabilizes EGFR. ( A ) A549 cells were transfected with non-targeting control scrambled (NSS) siRNA or BUB1siRNA. 48 hours post-transfection cells were cross-linked with 100 μM DSS for 30 minutes followed by 30 ng/mL EGF for an additional 30 minutes. Resulting lysates were resolved on SDS-PAGE gels and probed with indicated antibodies. ( B ) Quantitation of western blots from ( A ) only the monomer species of EGFR is plotted. Control siRNA (NSS) transfected, EGF treated lanes were set as 1 fold and used as a baseline for estimating fold enrichment in other samples. ( C ) Quantitation of pEGFR and EGFR dimers from SDS and EGF treated lanes only (lanes 4 and 8 only in A ). NSS transfected lane was set as 1 fold and used as a baseline for estimating fold enrichment in BUB1 siRNA transfected samples. ( D ) Gene expression values from non-metastatic adenocarcinoma samples (N=331) from TCGA lung dataset were log 2 transformed and median centered and correlation coefficient (r) was calculated. BUB1 and EGFR expression is expressed as log 2 transformed values. Correlation coefficient and p-value are listed.

    Journal: Aging (Albany NY)

    Article Title: Budding uninhibited by benzimidazoles-1 (BUB1) regulates EGFR signaling by reducing EGFR internalization

    doi: 10.18632/aging.204820

    Figure Lengend Snippet: BUB1 depletion stabilizes EGFR. ( A ) A549 cells were transfected with non-targeting control scrambled (NSS) siRNA or BUB1siRNA. 48 hours post-transfection cells were cross-linked with 100 μM DSS for 30 minutes followed by 30 ng/mL EGF for an additional 30 minutes. Resulting lysates were resolved on SDS-PAGE gels and probed with indicated antibodies. ( B ) Quantitation of western blots from ( A ) only the monomer species of EGFR is plotted. Control siRNA (NSS) transfected, EGF treated lanes were set as 1 fold and used as a baseline for estimating fold enrichment in other samples. ( C ) Quantitation of pEGFR and EGFR dimers from SDS and EGF treated lanes only (lanes 4 and 8 only in A ). NSS transfected lane was set as 1 fold and used as a baseline for estimating fold enrichment in BUB1 siRNA transfected samples. ( D ) Gene expression values from non-metastatic adenocarcinoma samples (N=331) from TCGA lung dataset were log 2 transformed and median centered and correlation coefficient (r) was calculated. BUB1 and EGFR expression is expressed as log 2 transformed values. Correlation coefficient and p-value are listed.

    Article Snippet: Antibodies to pAKT (cat# 4060), total AKT (cat# 9272), pEGFR(Y845) (cat #2231), pEGFR(Y1092), pEGFR (Y1068) (cat# 3777), pEGFR (Y1173), total EGFR (cat # 4267; # 2232), Her2/ErbB2, c-Met, pFAK, FAK, pErk1/2 (42/44) (cat # 9101; cat # 4370), Erk1/2 (42/44) (cat # 4695) and GAPDH (all from Cell Signaling), β-adaptin (BD Biosciences, cat # 610382), EEA1 (Ab70521), and Actin were from Abcam.

    Techniques: Transfection, SDS Page, Quantitation Assay, Western Blot, Expressing, Transformation Assay

    BUB1 inhibition reduces EGFR activation. MDA-MB-231 ( A ) NCI-H358 ( B ) and MRC5 ( C ) cells were serum starved and pre-treated with 10 μM 2OH-BNPP1 for 1 hour followed by 50 ng/mL EGF. Cells were harvested at the indicated time-points (10-180 minutes) after EGF treatment. Whole cell lysates from these samples were resolved on SDS-PAGE gels and transferred to PVDF membranes. The membranes were blocked with 5% de-fatted milk-TBST and probed with pEGFR (Y845), pAKT (S473), and pERK1/2 antibodies. The blots were also probed with antibodies raised against total proteins.

    Journal: Aging (Albany NY)

    Article Title: Budding uninhibited by benzimidazoles-1 (BUB1) regulates EGFR signaling by reducing EGFR internalization

    doi: 10.18632/aging.204820

    Figure Lengend Snippet: BUB1 inhibition reduces EGFR activation. MDA-MB-231 ( A ) NCI-H358 ( B ) and MRC5 ( C ) cells were serum starved and pre-treated with 10 μM 2OH-BNPP1 for 1 hour followed by 50 ng/mL EGF. Cells were harvested at the indicated time-points (10-180 minutes) after EGF treatment. Whole cell lysates from these samples were resolved on SDS-PAGE gels and transferred to PVDF membranes. The membranes were blocked with 5% de-fatted milk-TBST and probed with pEGFR (Y845), pAKT (S473), and pERK1/2 antibodies. The blots were also probed with antibodies raised against total proteins.

    Article Snippet: Antibodies to pAKT (cat# 4060), total AKT (cat# 9272), pEGFR(Y845) (cat #2231), pEGFR(Y1092), pEGFR (Y1068) (cat# 3777), pEGFR (Y1173), total EGFR (cat # 4267; # 2232), Her2/ErbB2, c-Met, pFAK, FAK, pErk1/2 (42/44) (cat # 9101; cat # 4370), Erk1/2 (42/44) (cat # 4695) and GAPDH (all from Cell Signaling), β-adaptin (BD Biosciences, cat # 610382), EEA1 (Ab70521), and Actin were from Abcam.

    Techniques: Inhibition, Activation Assay, SDS Page

    Inhibition of BUB1 kinase activity reduces EGFR active dimers without affecting inactive-EGFR dimers. A549 ( A ) MRC5 ( B ) and MDA-MB-231-1833 ( C ) cells were serum starved for 3-4 hours, pretreated with 2OH-BNPP1 (10 μM), erlotinib (10 μM) or cetuximab (50 μg/mL) for 1 hour followed by EGF (50 ng/mL) for 10 min. DSS (200 μM) was added for an additional 20 minutes. Total cell lysates were made, resolved on 3-8% gels and probed with pEGFR (Y845), EGFR, Her2 and c-Met antibodies.

    Journal: Aging (Albany NY)

    Article Title: Budding uninhibited by benzimidazoles-1 (BUB1) regulates EGFR signaling by reducing EGFR internalization

    doi: 10.18632/aging.204820

    Figure Lengend Snippet: Inhibition of BUB1 kinase activity reduces EGFR active dimers without affecting inactive-EGFR dimers. A549 ( A ) MRC5 ( B ) and MDA-MB-231-1833 ( C ) cells were serum starved for 3-4 hours, pretreated with 2OH-BNPP1 (10 μM), erlotinib (10 μM) or cetuximab (50 μg/mL) for 1 hour followed by EGF (50 ng/mL) for 10 min. DSS (200 μM) was added for an additional 20 minutes. Total cell lysates were made, resolved on 3-8% gels and probed with pEGFR (Y845), EGFR, Her2 and c-Met antibodies.

    Article Snippet: Antibodies to pAKT (cat# 4060), total AKT (cat# 9272), pEGFR(Y845) (cat #2231), pEGFR(Y1092), pEGFR (Y1068) (cat# 3777), pEGFR (Y1173), total EGFR (cat # 4267; # 2232), Her2/ErbB2, c-Met, pFAK, FAK, pErk1/2 (42/44) (cat # 9101; cat # 4370), Erk1/2 (42/44) (cat # 4695) and GAPDH (all from Cell Signaling), β-adaptin (BD Biosciences, cat # 610382), EEA1 (Ab70521), and Actin were from Abcam.

    Techniques: Inhibition, Activity Assay

    BUB1 inhibitor reduces endocytosis of active EGFR in MDA-MB-231-1833 cells. ( A ) Cells were plated on glass coverslips, serum starved for 3-4 hours and pretreated with 2OH-BNPP1 (10 μM) or erlotinib (10 μM) for 1 hour followed by EGF treatment (50 ng/mL). Cells were fixed at different time points (5, 20, 40 and 80 minutes) post EGF treatment and processed for staining with pEGFR (Y1068) and EEA1 antibodies. Representative confocal images 20 minutes post EGF treatment are shown. ( B ) co-localization of pEGFR (Y1068) with EEA1 was estimated on ImageJ using JACOMP plugin. Data at 20 min post EGF treatment is plotted. Two-sided students t-test was performed on MS-Excel (p values, ** = 0.00097, ***=3.17 X 10 -5 ).

    Journal: Aging (Albany NY)

    Article Title: Budding uninhibited by benzimidazoles-1 (BUB1) regulates EGFR signaling by reducing EGFR internalization

    doi: 10.18632/aging.204820

    Figure Lengend Snippet: BUB1 inhibitor reduces endocytosis of active EGFR in MDA-MB-231-1833 cells. ( A ) Cells were plated on glass coverslips, serum starved for 3-4 hours and pretreated with 2OH-BNPP1 (10 μM) or erlotinib (10 μM) for 1 hour followed by EGF treatment (50 ng/mL). Cells were fixed at different time points (5, 20, 40 and 80 minutes) post EGF treatment and processed for staining with pEGFR (Y1068) and EEA1 antibodies. Representative confocal images 20 minutes post EGF treatment are shown. ( B ) co-localization of pEGFR (Y1068) with EEA1 was estimated on ImageJ using JACOMP plugin. Data at 20 min post EGF treatment is plotted. Two-sided students t-test was performed on MS-Excel (p values, ** = 0.00097, ***=3.17 X 10 -5 ).

    Article Snippet: Antibodies to pAKT (cat# 4060), total AKT (cat# 9272), pEGFR(Y845) (cat #2231), pEGFR(Y1092), pEGFR (Y1068) (cat# 3777), pEGFR (Y1173), total EGFR (cat # 4267; # 2232), Her2/ErbB2, c-Met, pFAK, FAK, pErk1/2 (42/44) (cat # 9101; cat # 4370), Erk1/2 (42/44) (cat # 4695) and GAPDH (all from Cell Signaling), β-adaptin (BD Biosciences, cat # 610382), EEA1 (Ab70521), and Actin were from Abcam.

    Techniques: Staining